Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Post by fairweather1on Nov 06, 2014 3:28pm
201 Views
Post# 23103489

VERY interesting press release

VERY interesting press release
First off, .19 per share is not a shabby quarter at all given the challenge they must be facing keeping staff from jumping ship, and I think Q3 included a summer shutdown, if I'm not mistaken.

Q4 will likely be even more challenging depending on how Ford/AM handle transition, but perhaps the most interesting component in this PR is the comment about a cancelled dividend and ongoing diversification efforts in the same sentence.  With all the cash they have, paying another 6 cents wouldn't hurt ... unless perhaps they have an acquisition target that they feel would be better leveraged with an extra million or so that would otherwise go to dividends.

The pessimistic view would be that it could be smoke and mirrors to make it look like they are working hard to diversify, but as I mentioned in an earlier post, I wouldn't write off new business just yet.

Not that it relates to the current dividend, but I also think the GM litigation thing will be seen through to the end (may take a couple quarters, but that would be with a skeletonized mgt), and even if they only got 50%, and you took off another million or two in legal costs, that would still be over 50 cents per share.  That would be huge.

Should be an interesting finish no matter what happens.

Bullboard Posts